These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 873714)

  • 61. Failure of vitamin B6 to reverse the L-dopa effect in patients on a dopa decarboxylase inhibitor.
    Klawans HL; Ringel SP; Shenker DM
    J Neurol Neurosurg Psychiatry; 1971 Dec; 34(6):682-6. PubMed ID: 5158783
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Correlation of clinical symptoms, HVA and 5-HIAA in csf and plasma L-DOPA in Parkinsonian patients treated with L-DOPA and L-DOPA + RO 4-4602.
    Campanella G; Algeri S; Cerletti C; Dolfini E; Jori A; Rinaldi F
    Eur J Clin Pharmacol; 1977 Apr; 11(4):255-61. PubMed ID: 862646
    [No Abstract]   [Full Text] [Related]  

  • 63. Madopar HBS: slow-release levodopa and benserazide in parkinsonian patients presenting marked fluctuations in symptoms on standard L-dopa treatment.
    Jensen NO; Dupont E; Hansen E; Mikkelsen B; Mikkelsen BO
    Eur Neurol; 1987; 27 Suppl 1():68-72. PubMed ID: 3428310
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A comparison of the effects of decarboxylase inhibitors on L-dopa-induced circling behavior and the conversion of dopa to dopamine in the brain.
    Goodale DB; Moore KE
    Life Sci; 1976 Sep; 19(5):701-6. PubMed ID: 957902
    [No Abstract]   [Full Text] [Related]  

  • 65. L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment.
    Bergonzi P; Chiurulla C; Gambi D; Mennuni G; Pinto F
    Acta Neurol Belg; 1975; 75(1):5-10. PubMed ID: 1202895
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Outcome of Parkinsonism after two years of levodopa plus R04-4602 (author's transl)].
    Faglioni P; Gasparini M; Spinnler H
    Riv Patol Nerv Ment; 1975; 96(4):270-86. PubMed ID: 785578
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients.
    Admani AK; Verma S; Cordingley GJ; Harris RI
    Pharmatherapeutica; 1985; 4(2):132-40. PubMed ID: 4059292
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [2-year experiences with a combination treatment of Parkinsonism with L-dopa and a decarboxylase inhibitor (Benserazid, Ro 4-4602)].
    Birkmayer W; Linauer W; Mentasti M; Riederer P
    Wien Med Wochenschr; 1974 Jun; 124(22):340-4. PubMed ID: 4275492
    [No Abstract]   [Full Text] [Related]  

  • 69. Inhibition of a minor pathway of L-dopa metabolism in the intestinal lumen using a decarboxylase inhibitor (Ro 4-4602).
    Bakke OM; Scheline RR
    J Pharm Pharmacol; 1974 May; 26(5):377-9. PubMed ID: 4152920
    [No Abstract]   [Full Text] [Related]  

  • 70. Alpha-methyldopa-chlorpromazine combination in schizophrenic patients.
    Chouinard G; Annable L
    Neuropsychobiology; 1976; 2(2-3):118-26. PubMed ID: 796755
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A placebo-controlled clinical trial of remoxipride and chlorpromazine in newly admitted schizophrenic patients with acute exacerbation.
    Chouinard G
    Acta Psychiatr Scand Suppl; 1990; 358():111-9. PubMed ID: 1978469
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Blood-brain barrier to carbidopa (MK-486) and Ro 4-4602, peripheral dopa decarboxylase inhibitors.
    Clark WG; Oldendorf WH; Dewherst WG
    J Pharm Pharmacol; 1973 May; 25(5):416-8. PubMed ID: 4146401
    [No Abstract]   [Full Text] [Related]  

  • 73. [5 years of experience in the treatment of parkinsonism with L-dopa and its combination with Ro4-4602].
    Romero S; Chouza C; Gomensoro JB
    Neurol Neurocir Psiquiatr; 1976; 17(4):239-54. PubMed ID: 1018727
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Induction of aromatic-L-amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism.
    Boomsma F; Meerwaldt JD; Man in 't Veld AJ; Hovestadt A; Schalekamp MA
    Ann Neurol; 1989 Jun; 25(6):624-8. PubMed ID: 2742363
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The effect of L-dopa and an inhibitor of peripheral decarboxylation on glucose metabolism in brain.
    Tyce GM
    J Neurochem; 1976 Dec; 27(6):1397-403. PubMed ID: 1003214
    [No Abstract]   [Full Text] [Related]  

  • 76. Liver function and gastric acid secretion in parkinsonian patients under prolonged treatment with L-dopa and a peripheral decarboxylase inhibitor.
    Streifler M; Kesten M; Loewenthal M; Aldor T; Gilat T
    Eur Neurol; 1976; 14(1):68-76. PubMed ID: 1253804
    [TBL] [Abstract][Full Text] [Related]  

  • 77. ["Beginning and end of dose" dyskinesias caused by L-DOPA].
    Lhermitte F; Agid Y; Signoret JL; Studler JM
    Rev Neurol (Paris); 1977 May; 133(5):297-308. PubMed ID: 897439
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Inhibition of tryptophan hydroxylase by benserazide and other catechols.
    Johansen PA; Wolf WA; Kuhn DM
    Biochem Pharmacol; 1991 Feb; 41(4):625-8. PubMed ID: 1997008
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Bromocriptine alone or associated with L-dopa plus benserazide in Parkinson's disease.
    Caraceni TA; Celano I; Parati E; Girotti F
    J Neurol Neurosurg Psychiatry; 1977 Dec; 40(12):1142-6. PubMed ID: 591982
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Human pharmacokinetics of long term 5-hydroxytryptophan combined with decarboxylase inhibitors.
    Magnussen I; Van Woert MH
    Eur J Clin Pharmacol; 1982; 23(1):81-6. PubMed ID: 6182005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.